A phase II study of alternating cycles of split course radiation therapy and gemcitabine chemotherapy for inoperable pancreatic or biliary tract carcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 28, Issue 3, 2005, Pages 234-241

  Lin, Lilie L ^a   Picus, Joel ^a   Drebin, J A ^a,b   Linehan, David C ^a   Solis, Juan ^a,c   Strasberg, Steven M ^a   Tan, Benjamin ^a   Thorstad, Wade L ^a   Myerson, Robert J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HOSPITAL CARLOS VAN BUREN   (Chile)

Author keywords

Gemcitabine; Pancreatic carcinoma; Radiation therapy

Indexed keywords

GEMCITABINE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASCITES; BILE DUCT CARCINOMA; BLOOD TOXICITY; BRADYCARDIA; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY; HYPOGLYCEMIA; HYPONATREMIA; HYPOTENSION; INOPERABLE CANCER; KIDNEY FAILURE; LEG EDEMA; LUNG EDEMA; MALE; NAUSEA; NEUTROPENIA; PAIN; PANCREAS CARCINOMA; PHASE 2 CLINICAL TRIAL; RASH; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BILE DUCT NEOPLASMS; CARCINOMA; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; INTESTINE, SMALL; LIFE TABLES; LYMPHATIC IRRADIATION; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PALLIATIVE CARE; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROSPECTIVE STUDIES; RADIATION INJURIES; RADIATION-SENSITIZING AGENTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 20444374053     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000156920.11091.12     Document Type: Article

References (24)

1. Jemal A, Thomas A, Murray T, et al. Cancer Statistics, 2002. CA Cancer J Clin. 2002;52:23-47.
2. Evans DB, Abbruzzese JL, Willlett CG. Cancer of the pancreas. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 6th ed. Philadelphia: Lippincott-Raven; 2001:1130-1145.
3. Moertel CG, Childs DS Jr, Reitemeier RJ, et al. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet. 1969;2:865-867.
4. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer. 1981;48:1705-1710.
5. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer. 1987;59:2006-2010.
6. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst. 1988;80:751-755.
7. Klaassen DJ, MacIntyre JM, Catton GE, et al. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil-an Eastern Cooperative Oncology Group study. J Clin Oncol. 1985;3:373-378.
8. Kornek GV, Schratter-Sehn A, Marczell A, et al. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin. Br J Cancer. 2000;82:98-103.
9. Safran H, Moore T, Iannitti D, et al. Paclitaxel and concurrent radiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2001;49:1275-1279.
10. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
11. Mason K, Milas L, Hunter NR, et al. Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int J Radiat Oncol Biol Phys. 1999;44:1125-1135.
12. Lawrence TS, Eisbruch A, Shewach DS. Gemicitabine-mediated radiosensitization. Semin Oncol. 1997;24:24.
13. Yokes EE, Mauer AM, Hoffman PC, et al. Combined modality therapy in non-small cell lung and esophageal cancer: a phase I dose-escalation study of docetaxel with concurrent radiotherapy. Semin Oncol. 1998;25:28-32.
14. Myerson RJ, Valentini V, Birnbaum EH, et al. A phase I/II trial of three-dimensionally planned concurrent boost radiotherapy and protracted venous infusion of 5-FU chemotherapy for locally advanced rectal carcinoma. Int J Radiat Oncol Biol Phys. 2001;50:1299-1308.
15. Pilepich MV, Miller HH. Preoperative irradiation in carcinoma of the pancreas. Cancer. 1980;46:1945-1949.
16. Bajetta E, Di Bartolomeo M, Stani SC, et al. Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility study. Int J Radiat Oncol Biol Phys. 1999;45:285-289.
17. Blackstock AW, Bernard SA, Richards F, et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol. 1999;17:2208-2212.
18. Pipas JM, Mitchell SE, Barth RJ Jr, et al. Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 2001;50:1317-1322.
19. Crane CH, Abbruzzese JL, Evans DB, et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys. 2002;52:1293-1302.
20. McGinn CJ, Zalupski MM, Shureiqi I, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2001;19:4202-4208.
21. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs. 1994;12:29-34.
22. Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002;20:3270-3275.
23. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-1024.
24. Fleming ID, Cooper JS, Henson DE, et al. AJCC Cancer Staging Manual, 5th ed. Philadelphia: Lippincott-Raven; 1997.